Business Description
Respiratorius AB
ISIN : SE0023314315
Total Employee Number:
1Compare
Compare
Traded in other countries / regions
RESP.SwedenHF00.Germany IPO Date
2012-07-05Description
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | N/A |
N/A
|
N/A
| |||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 16.14 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | -30.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.63 | |||||
9-Day RSI | 74.31 | |||||
14-Day RSI | 70.36 | |||||
3-1 Month Momentum % | 65.85 | |||||
6-1 Month Momentum % | 45.57 | |||||
12-1 Month Momentum % | -68.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.46 | |||||
Quick Ratio | 5.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -39.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 11506.45 | |||||
Operating Margin % | -21551.61 | |||||
Net Margin % | -21545.16 | |||||
EBITDA Margin % | -10300 | |||||
FCF Margin % | -11012.9 | |||||
OCF Margin % | -11012.9 | |||||
ROE % | -22.85 | |||||
ROA % | -22.02 | |||||
ROIC % | -23.16 | |||||
ROC (Joel Greenblatt) % | -145.35 | |||||
ROCE % | -22.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 650 | |||||
PB Ratio | 0.89 | |||||
Price-to-Tangible-Book | 6.25 | |||||
EV-to-EBIT | -3.54 | |||||
EV-to-EBITDA | -7.42 | |||||
EV-to-Revenue | 764.78 | |||||
EV-to-FCF | -7.52 | |||||
| Price-to-Net-Current-Asset-Value | 6.25 | |||||
Earnings Yield (Greenblatt) % | -28.21 | |||||
FCF Yield % | -14.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Respiratorius AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.031 | ||
| EPS (TTM) (kr) | -0.95 | ||
| Beta | 0.8925 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.62 | ||
| Volatility % | 77.99 | ||
| 14-Day RSI | 70.36 | ||
| 14-Day ATR (kr) | 0.27766 | ||
| 20-Day SMA (kr) | 2.6085 | ||
| 12-1 Month Momentum % | -68.01 | ||
| 52-Week Range (kr) | 1.19 - 7.5 | ||
| Shares Outstanding (Mil) | 7.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Respiratorius AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Respiratorius AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 119 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 28 days | ||
| General meeting for 2025 | 2026-06-09 15:00 | 2.39 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-26 | 2.40 (+6.67%) | ||
| Annual report for 2025 | 2026-05-15 | 2.82 (+12.80%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-10 | 1.60 (-4.19%) | ||
| Third quarter earnings results for 2025 | 2025-11-11 | 1.86 (+3.34%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 6.74 (-2.32%) | ||
| General meeting for 2024 | 2025-05-21 15:00 | 4.52 (-0.22%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 4.52 (-0.22%) |
Show
Entries
Respiratorius AB Frequently Asked Questions
What is Respiratorius AB(XSAT:RESP)'s stock price today?
The current price of XSAT:RESP is kr3.00. The 52 week high of XSAT:RESP is kr7.50 and 52 week low is kr1.19.
When is next earnings date of Respiratorius AB(XSAT:RESP)?
The next earnings date of Respiratorius AB(XSAT:RESP) is 2026-08-11.
Does Respiratorius AB(XSAT:RESP) pay dividends? If so, how much?
Respiratorius AB(XSAT:RESP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Respiratorius AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers